Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses (2016 - 2023)

Historic Other Accumulated Expenses for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Q2 2023 value amounting to $1000.0.

  • Lineage Cell Therapeutics' Other Accumulated Expenses fell 9000.0% to $1000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $1000.0, marking a year-over-year decrease of 9000.0%. This contributed to the annual value of $178000.0 for FY2021, which is 187777.78% up from last year.
  • Lineage Cell Therapeutics' Other Accumulated Expenses amounted to $1000.0 in Q2 2023, which was down 9000.0% from $37000.0 recorded in Q1 2023.
  • Lineage Cell Therapeutics' 5-year Other Accumulated Expenses high stood at $492000.0 for Q2 2021, and its period low was $1000.0 during Q2 2023.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $31000.0 (2022), whereas its average is $78187.5.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Accumulated Expenses surged by 187777.78% in 2021 and then plummeted by 9796.75% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Other Accumulated Expenses stood at $4000.0 in 2019, then skyrocketed by 125.0% to $9000.0 in 2020, then soared by 1877.78% to $178000.0 in 2021, then plummeted by 85.96% to $25000.0 in 2022, then tumbled by 96.0% to $1000.0 in 2023.
  • Its Other Accumulated Expenses stands at $1000.0 for Q2 2023, versus $37000.0 for Q1 2023 and $25000.0 for Q3 2022.